For the quarter ending 2025-09-30, GRTX had -$757K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,388 | -2,667 |
| Depreciation and amortization | 0 | 0 |
| Share-based compensation expense | 91 | 227 |
| Write-off of acquired intangible asset | 0 | - |
| Write-off of goodwill | 0 | - |
| Change in fair value of warrants | 0 | -294 |
| Gain on disposal of property and equipment | 0 | - |
| Deferred tax benefit | 0 | - |
| Prepaid expenses and other current assets | -289 | -360 |
| Other assets | 0 | 1 |
| Accounts payable | 232 | -1,073 |
| Accrued expense | 19 | -246 |
| Other liabilities | 0 | 0 |
| Cash used in operating activities | -757 | -3,694 |
| Proceeds from sale of property and equipment | 0 | - |
| Cash provided by investing activities | 0 | - |
| Proceeds from the sale of common stock in private placement | 0 | 635 |
| Cash provided by financing activities | 0 | 635 |
| Net decrease in cash and cash equivalents | -757 | -3,059 |
| Cash and cash equivalents at beginning of period | 8,289 | - |
| Cash and cash equivalents at end of period | 4,473 | - |
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)